Acticor Biotech SAS (ALACT.PA)
4.99 €
-0.01 (-0.20%)
Rating:
Recommendation:
-
| Symbol | ALACT.PA |
|---|---|
| Price | 4.99 € |
| Beta | 0.000 |
| Volume Avg. | 0.00M |
| Market Cap | 66.059M |
| Shares () | - |
| 52 Week Range | 4.9-11.0 |
| 1y Target Est | - |
| DCF Unlevered | ALACT.PA DCF -> | |
|---|---|---|
| DCF Levered | ALACT.PA LDCF -> | |
| ROE | -379.15% | Strong Sell |
| ROA | -128.53% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -350.56% | Strong Sell |
| P/E | -3.37 | Strong Sell |
| P/B | -23.46 | Strong Sell |
About
Download (Excel)Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.